A year and a half after Roche AG handed back rights, Evotec AG has found a new home for its NMDA antagonist portfolio, in a licensing deal with Janssen Pharmaceuticals Inc. worth a potential $75 million up to launch. Read More
It's a cell-eat-cell world in there. And apparently, that's a good thing, too. "In the body, almost any cell can eat other cells," Kodi Ravichandran told BioWorld International. "Especially their neighbors who are dying." Read More
Dutalys GmbH, an early stage company developing a bispecific antibody platform, entered a research collaboration with a top 10 pharmaceutical firm that could evolve into a product licensing alliance. Read More
Six years after building an acquisition-led position in the research and diagnostic antibody space, MorphoSys AG is exiting the field, via a €53 million (US$69.7 million) cash sale of its Abd Serotec unit to Bio-Rad Laboratories Inc. Read More
The French vaccines manufacturing technology company Vivalis SA is acquiring Austrian vaccines discoverer and developer Intercell AG, of Vienna, in an all-share deal valued at €133 million (US$175 million). Read More
Breaking out the champagne may not have been the appropriate reaction, but Biotie Therapies Oyj had reason to celebrate Friday, as the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended approval for its alcohol dependence drug Selincro (nalmefene). Read More
• Karus Therapeutics Ltd., of Southhampton, UK, entered a collaboration with the Babraham Institute, of Cambridge, UK, to further characterize treatments for inflammatory diseases through the regulation of phosphatidylinositol-3-kinase (PI3K) – a family of enzymes important to immune cell function. Read More
